Peptide Sequence Determines the Efficacy of Single-Dose AAV-Vectorized GLP-1R Agonists in Diet-Induced Obese Mice
Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide produce substantial weight loss and glycemic improvement, but their long-term efficacy depends on sustained adherence to chronic dosing. Adeno-associated virus (AAV) gene therapy could, in principle, provide durable GLP-1R agonist (GLP-1RA) exposure from a single administration, but the degree of peptide…
A study examining the impact of peptide sequencing on the effectiveness of single-dose AAV-vectorized GLP-1R agonists in diet-induced obese mice has revealed promising results. Four self-complementary AAV (scAAV) constructs were created, encoding native human GLP-1(7-36), a DPP-IV-resistant Gly8-GLP-1(7-36) variant, Exendin-4, and an Exendin-4 human IgG4 Fc fusion protein.
These constructs were validated to secrete functional GLP-1R agonists in vitro, with varying concentrations of GLP-1 constructs spanning nearly four orders of magnitude 72 hours post-transfection. In diet-induced obese mice, only the Ex4 and Ex4-Fc vectors produced significant reductions in body weight, food intake, fat mass, fasting insulin, and improved oral glucose tolerance compared to the vehicle control. These effects were observed up to 21 days post-single dose administration.
While the transcript levels of all four constructs were comparable in both brain and liver tissues, measurable peptide products in plasma and brain lysates aligned with the in vitro supernatant screen rankings. GLP-1 and Gly8 groups were indistinguishable from endogenous background levels. Engineering peptides to improve translation and secretion efficiency, as well as circulating plasma stability, could optimize vectorized GLP-1RA therapeutics.
Rewritten by urgent.news; may contain errors — check the original.
Source: biorxiv.org